An open study to compare the efficacy of immunoglobulin administered subcutaneously (SCIG) with current best practice in patients with Complex Regional Pain Syndrome (CRPS)

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 07 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Immune globulin (Primary) ; Immune globulin
Indications Complex regional pain syndromes
Focus Proof of concept; Therapeutic Use

Most Recent Events

24 Sep 2019 Status changed from active, no longer recruiting to discontinued.
06 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by UKCRN.
15 Mar 2012 Actual initiation date 5 Nov 2009 added as reported by EudraCT.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight